JP2019533652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533652A5 JP2019533652A5 JP2019517257A JP2019517257A JP2019533652A5 JP 2019533652 A5 JP2019533652 A5 JP 2019533652A5 JP 2019517257 A JP2019517257 A JP 2019517257A JP 2019517257 A JP2019517257 A JP 2019517257A JP 2019533652 A5 JP2019533652 A5 JP 2019533652A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cdk1
- clk2
- cell
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 7
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 6
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 6
- 102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 description 6
- 101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 CC(C)[n]1c2nc(N[C@@]3C*CC3)nc(Nc3cccc(Cl)c3)c2nc1 Chemical compound CC(C)[n]1c2nc(N[C@@]3C*CC3)nc(Nc3cccc(Cl)c3)c2nc1 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000001256 adenosarcoma Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402876P | 2016-09-30 | 2016-09-30 | |
| US62/402,876 | 2016-09-30 | ||
| PCT/US2017/054442 WO2018064545A1 (en) | 2016-09-30 | 2017-09-29 | Dual clk/cdk1 inhibitors for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533652A JP2019533652A (ja) | 2019-11-21 |
| JP2019533652A5 true JP2019533652A5 (cg-RX-API-DMAC7.html) | 2020-11-12 |
Family
ID=61760971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517257A Pending JP2019533652A (ja) | 2016-09-30 | 2017-09-29 | がんを処置するための二重ｃｌｋ／ｃｄｋ１阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10722515B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4086257A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019533652A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114149432B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018064545A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| CN114149432B (zh) * | 2016-09-30 | 2024-07-05 | 斯坦福国际研究院 | 用于癌症治疗的双重clk/cdk1抑制剂 |
| EP3813826A4 (en) * | 2018-06-26 | 2022-07-06 | BioSplice Therapeutics, Inc. | Methods of treating cancer using a clk inhibitor |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| CN113384703B (zh) * | 2021-06-21 | 2023-03-10 | 深圳市第二人民医院(深圳市转化医学研究院) | Dhx34基因的表达抑制剂在制备抑制肝癌细胞转移和侵袭的药物中的应用 |
| CN120289460A (zh) * | 2024-01-09 | 2025-07-11 | 中国科学院合肥物质科学研究院 | 含有嘌呤环的化合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US7091346B1 (en) | 1995-11-01 | 2006-08-15 | Novartis Ag | Purine derivatives and processes for their preparation |
| GB9903762D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| FR2793794B1 (fr) * | 1999-05-21 | 2001-07-27 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| AU2277201A (en) * | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Novel purines |
| CA2394654A1 (en) * | 1999-12-17 | 2001-06-21 | Manfred Weigele | Proton pump inhibitors |
| DE60031886T2 (de) * | 1999-12-17 | 2007-09-06 | Ariad Pharmaceuticals, Inc., Cambridge | Purinderivate |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2009085226A2 (en) * | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| WO2013144532A1 (en) * | 2012-03-30 | 2013-10-03 | Astrazeneca Ab | 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents |
| US9872874B2 (en) * | 2012-05-15 | 2018-01-23 | Cyclacel Limited | Dosage regimen for sapacitabine and seliciclib |
| EP2968536B1 (en) * | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| UA115388C2 (uk) * | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| JP2019517257A (ja) | 2016-05-31 | 2019-06-24 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 幹細胞をニューロンに分化するインビトロ法、及びこの方法を用いて生成されたニューロン |
| CN114149432B (zh) | 2016-09-30 | 2024-07-05 | 斯坦福国际研究院 | 用于癌症治疗的双重clk/cdk1抑制剂 |
-
2017
- 2017-09-29 CN CN202111328981.9A patent/CN114149432B/zh active Active
- 2017-09-29 EP EP22165211.8A patent/EP4086257A1/en not_active Withdrawn
- 2017-09-29 WO PCT/US2017/054442 patent/WO2018064545A1/en not_active Ceased
- 2017-09-29 US US16/334,229 patent/US10722515B2/en active Active
- 2017-09-29 JP JP2019517257A patent/JP2019533652A/ja active Pending
- 2017-09-29 EP EP17857539.5A patent/EP3518925A4/en not_active Withdrawn
- 2017-09-29 CN CN201780067717.XA patent/CN109937039A/zh active Pending
-
2020
- 2020-05-28 US US16/886,290 patent/US11337981B2/en active Active